Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 29, 2013, Pages 12006-12011

  Cheema, Tooba A ^a   Wakimoto, Hiroaki ^a   Fecci, Peter E ^a   Ning, Jianfang ^a   Kuroda, Toshihiko ^a   Jeyaretna, Deva S ^a   Martuza, Robert L ^a   Rabkin, Samuel D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antiangiogenesis; Immunotherapy; Virotherapy

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; ONCOLYTIC HERPES VIRUS;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STEM CELL; CELL HETEROGENEITY; CONTROLLED STUDY; GLIOBLASTOMA; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SURVIVAL; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANTIANGIOGENESIS; IMMUNOTHERAPY; VIROTHERAPY;

ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GLIOBLASTOMA; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INTERLEUKIN-12; KAPLAN-MEIER ESTIMATE; MICE; MICE, INBRED C57BL; NEOPLASTIC STEM CELLS; ONCOLYTIC VIROTHERAPY; SIMPLEXVIRUS;

EID: 84880376084     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1307935110     Document Type: Article

References (50)

1. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492-507.
2. Dirks PB (2010) Brain tumor stem cells: The cancer stem cell hypothesis writ large. Mol Oncol 4(5):420-430.
3. Fecci PE, et al. (2006) Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66(6):3294-3302.
4. Rolle CE, Sengupta S, Lesniak MS (2012) Mechanisms of immune evasion by gliomas. Adv Exp Med Biol 746:53-76.
5. Wei J, et al. (2010) Glioma-Associated cancer-initiating cells induce immunosuppression. Clin Cancer Res 16(2):461-473.
6. Di Tomaso T, et al. (2010) Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res 16(3):800-813.
7. Castriconi R, et al. (2009) NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol 182(6):3530-3539.
8. Ahmed N, et al. (2010) HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res 16(2):474-485.
9. Brown CE, et al. (2012) Stem-like tumor-initiating cells isolated from IL13Rá2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T cells. Clin Cancer Res 18(8):2199-2209.
10. Marumoto T, et al. (2009) Development of a novel mouse glioma model using lentiviral vectors. Nat Med 15(1):110-116.
11. Russell SJ, Peng KW, Bell JC (2012) Oncolytic virotherapy. Nat Biotechnol 30(7):658-670.
12. Wakimoto H, et al. (2009) Human glioblastoma-derived cancer stem cells: Establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res 69(8):3472-3481.
13. Ino Y (2009) A clinical study of a replication-competent, recombinant herpes simplex virus type 1 (G47delta) in patients with progressive glioblastoma. World Health Organization International Clinical Trials Registry. Available at http://apps.who.int/trialsearch/trial.aspx?trialid=JPRN- UMIN000002661.
14. Del Vecchio M, et al. (2007) Interleukin-12: Biological properties and clinical application. Clin Cancer Res 13(16):4677-4685.
15. Parker JN, et al. (2000) Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci USA 97(5):2208-2213.
16. Wong RJ, et al. (2001) Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther 12(3):253-265.
17. Varghese S, et al. (2006) Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther 13(3):253-265.
18. Dunn GP, Fecci PE, Curry WT (2012) Cancer immunoediting in malignant glioma. Neurosurgery 71(2):201-222, discussion 222-223.
19. Todo T, Martuza RL, Rabkin SD, Johnson PA (2001) Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 98(11):6396-6401.
20. Kanai R, et al. (2012) Oncolytic virus-mediated manipulation of DNA damage responses: Synergy with chemotherapy in killing glioblastoma stem cells. J Natl Cancer Inst 104(1):42-55.
21. Prestegarden L, et al. (2010) Glioma cell populations grouped by different cell type markers drive brain tumor growth. Cancer Res 70(11):4274-4279.
22. Beier CP, Beier D (2011) CD133 negative cancer stem cells in glioblastoma. Front Biosci (Elite Ed) 3:701-710.
23. Sgubin D, Wakimoto H, Kanai R, Rabkin SD, Martuza RL (2012) Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells. Stem Cells Transl Med 1(4):322-332.
24. Liu TC, Castelo-Branco P, Rabkin SD, Martuza RL (2008) Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. Mol Ther 16(6):1041-1047.
25. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H (2011) The brain tumor microenvironment. Glia 59(8):1169-1180.
26. Wu A, et al. (2010) Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro-oncol 12(11):1113-1125.
27. Lee J, et al. (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9(5):391-403.
28. Li A, et al. (2008) Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol Cancer Res 6(1):21-30.
29. Aghi M, Rabkin S (2005) Viral vectors as therapeutic agents for glioblastoma. Curr Opin Mol Ther 7(5):419-430.
30. Kaufman HL, et al. (2010) Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 17(3):718-730.
31. Todo T (2012) Active immunotherapy: Oncolytic virus therapy using HSV-1. Adv Exp Med Biol 746:178-186.
32. Sgadari C, Angiolillo AL, Tosato G (1996) Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 87(9):3877-3882.
33. Campanella GS, Colvin RA, Luster AD (2010) CXCL10 can inhibit endothelial cell proliferation independently of CXCR3. PLoS ONE 5(9):e12700.
34. Kerkar SP, et al. (2011) IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest 121(12):4746-4757.
35. Pegram HJ, et al. (2012) Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119(18):4133-4141.
36. Todo T, Ebright MI, Fong Y, Rabkin SD (2002) Oncolytic Herpes Simplex Virus (G207) Therapy: From Basic to Clinical. Tumor-Suppressing Viruses, Genes, and Drugs, ed Maruta H (Academic, San Diego), pp 45-75.
37. Liu TC, et al. (2006) Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res 12(22):6791-6799.
38. Aghi M, Rabkin SD, Martuza RL (2007) Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin- derived peptide. Cancer Res 67(2):440-444.
39. Hardcastle J, et al. (2010) Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol Ther 18(2):285-294.
40. Zhang W, et al. (2012) Bevacizumab with angiostatin-Armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma. Mol Ther 20(1):37-45.
41. Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nat Rev Cancer 8(8):579-591.
42. El Andaloussi A, Lesniak MS (2007) CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol 83(2):145-152.
43. Crane CA, Ahn BJ, Han SJ, Parsa AT (2012) Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: Implications for immunotherapy. Neuro-oncol 14(5):584-595.
44. Cao X, et al. (2009) Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance. Cancer Res 69(22):8700-8709.
45. Lund JM, Hsing L, Pham TT, Rudensky AY (2008) Coordination of early protective immunity to viral infection by regulatory T cells. Science 320(5880):1220-1224.
46. Alvarez-Breckenridge CA, Yu J, Kaur B, Caligiuri MA, Chiocca EA (2012) Deciphering the multifaceted relationship between oncolytic viruses and natural killer cells. Adv Virol 2012:702839.
47. Li M, Knight DA, Smyth MJ, Stewart TJ (2012) Sensitivity of a novel model of mammary cancer stem cell-like cells to TNF-related death pathways. Cancer Immunol Immunother 61(8):1255-1268.
48. Alvarez-Breckenridge CA, et al. (2012) NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med 18(12):1827-1834.
49. Markert JM, et al. (2012) Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12. J Virol 86(9):5304-5313.
50. Kuroda T, Martuza RL, Todo T, Rabkin SD (2006) Flip-Flop HSV-BAC: Bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases. BMC Biotechnol 6:40.